Literature DB >> 18560353

A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.

O Ndozangue-Touriguine1, M Sebbagh, D Mérino, O Micheau, J Bertoglio, J Bréard.   

Abstract

A pair of isogenic colon carcinoma cells, SW480 and 620, was used to investigate the mechanisms of acquired tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistance during tumour progression. Whereas primary tumour SW480 cells are sensitive to TRAIL-induced apoptosis, metastatic SW620 cells are resistant. The apoptotic signalling activated by TRAIL in SW480 cells is a type II pathway. We show that in SW620 cells, although caspase-8 is recruited and activated at the death-inducing-signalling complex and Bid is cleaved, this does not lead to caspase-9 activation. Comparison of Bcl-2, Bcl-xL and Mcl-1 levels in both cell lines showed no difference. In SW620 cells transfected with a tBid-GFP construct, tBid-GFP was correctly localized to the mitochondria. Thus, the resistance of SW620 cells is at the level of the mitochondria that can withstand large amounts of tBid. Although caspase-3 was directly cleaved by caspase-8 in SW620 cells to yield the p20 fragment, no further autocatalytic maturation into the p17 fragment was observed. We show that, in contrast to SW480 cells, the SW620 cell line expresses high amounts of X-linked inhibitor of apoptosis (XIAP). Downregulation of XIAP with bortezomib or small-interfering RNA was sufficient to restore the sensitivity of SW620 cells to TRAIL-induced apoptosis in the absence of SMAC/Diablo or cytochrome c release from the mitochondria. Thus, SW620 cells have developed a dual resistance to TRAIL-induced apoptosis: a block at the level of the mitochondria and, after a conversion to a type I pathway, an increased expression of XIAP which inhibits this pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18560353     DOI: 10.1038/onc.2008.197

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Authors:  Guillaume Jacquemin; Virginie Granci; Anne Sophie Gallouet; Najoua Lalaoui; Aymeric Morlé; Elisabetta Iessi; Alexandre Morizot; Carmen Garrido; Thierry Guillaudeux; Olivier Micheau
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1.

Authors:  Mian Ling Chen; Liu Sen Liang; Xiao Kang Wang
Journal:  Clin Exp Metastasis       Date:  2012-03-10       Impact factor: 5.150

3.  Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax.

Authors:  Subash C Gupta; Simone Reuter; Kanokkarn Phromnoi; Byoungduck Park; Padmanabhan S Hema; Mangalam Nair; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

4.  Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Authors:  A Morizot; D Mérino; N Lalaoui; G Jacquemin; V Granci; E Iessi; D Lanneau; F Bouyer; E Solary; B Chauffert; P Saas; C Garrido; O Micheau
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

5.  Continuous imaging of plasmon rulers in live cells reveals early-stage caspase-3 activation at the single-molecule level.

Authors:  Young-wook Jun; Sassan Sheikholeslami; Daniel R Hostetter; Cheryl Tajon; Charles S Craik; A Paul Alivisatos
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-01       Impact factor: 11.205

Review 6.  Mitochondria in relation to cancer metastasis.

Authors:  Bidur Bhandary; Anu Marahatta; Hyung-Ryong Kim; Han-Jung Chae
Journal:  J Bioenerg Biomembr       Date:  2012-12       Impact factor: 2.945

7.  New withanolides with TRAIL-sensitizing effect from Physalis pubescens L.

Authors:  Li-Xia Chen; Gui-Yang Xia; Hao He; Jian Huang; Feng Qiu; Xiao-Lin Zi
Journal:  RSC Adv       Date:  2016-05-26       Impact factor: 3.361

8.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 9.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

10.  XIAP is not required for human tumor cell survival in the absence of an exogenous death signal.

Authors:  John Sensintaffar; Fiona L Scott; Robert Peach; Jeffrey H Hager
Journal:  BMC Cancer       Date:  2010-01-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.